CD274 and cancer: Up-regulation of negative T cell co-stimulatory receptors, such as CTLA-4 and PD-1, on tumor-specific T cells to inhibit their effector function has been well studied in solid malignancies, and recent advances in immunotherapy led to the approval of PD-1 and PD-L1 antibodies in multiple cancer types and cancers with certain features.